Navigation Links
American Transplant Congress 2009
Date:3/23/2009

Experts Present New Research in Boston

MOUNT LAUREL, N.J. March 23 /PRNewswire/ -- The ninth annual American Transplant Congress 2009 (ATC) is the premier educational event in the field of basic and clinical transplantation. This joint meeting, sponsored by the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST), will occur from May 30 - June 4, 2009 at the John B. Hynes Convention Center in Boston, MA.

Controversial topics and important new data will be the focus of the Sunrise Symposia. Joint plenary sessions will showcase the top scoring abstracts, presented to the entire audience. On Sunday and Monday, there will be concurrent mid-day symposia centered on the timeliest issues in the field. "What's Hot, What's New" will be the final presentation.

ATC 09 will present two State-of-the-Art Addresses. Rudolf Jaenisch M.D., who established the Human Stem Cell Facility at the Whitehead Institute and is Professor of Biology at M.I.T., will speak on "Stem Cells and the Molecular Control of Pluripotency for Regenerative Medicine." Nobel prize winner, Philip Sharp M.D., Institute Professor at the David H. Koch Institute for Integrative Cancer Research at M.I.T. will present the topic of "RNA in Biology and Disease."

The meeting also features new, highly interactive sessions including the ATC New Investigator Career Highlight Forum. This discussion format will provide the opportunity for these individuals to introduce their research findings and obtain feedback from established investigators.

         ATC Highlights:
         State-of-the-Art Address - Rudolf Jaenisch M.D, M.I.T., Boston, MA
         State-of-the-Art Address - Philip Sharp, M.I.T., Boston, MA
         Special Interactive Sessions
         "What's Hot, What's New" Presentation
         Stem Cell & Islet Cell Research
         Infectious 
'/>"/>
SOURCE American Transplant Congress 2009
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. 22, 2014 ... leading global specialty pharmaceutical company, and Rhythm, a biopharmaceutical ... exclusive option to acquire Rhythm,s wholly owned subsidiary, Rhythm ... ghrelin agonist, for the treatment of diabetic gastroparesis and ... completed a successful Phase 2 trial of relamorelin for ...
(Date:10/22/2014)... Involution Studios , a healthcare software design ... Understanding Ebola . The goal of the ... follow informative tool for anyone wanting to know more ... , "As the news has spread in all directions ... not only a healthcare crisis with global impact, but ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: ... patients enrolled in the Phase I/II trial for its JAK1/JAK2 ... an oral presentation at the 52nd American Society of Hematology ... "Anemia is the most serious symptom associated with myelofibrosis, so ...
... Viruses have a bad rep—and rightly so. The ... itself makes it a destructive scourge to animals and ... the University of Maryland,s A. James Clark School of ... together by Professor Reza Ghodssi, is turning the tables, ...
... YORK, Dec. 6, 2010 See video from ... Novartis announced 24-month data showing that ... the treatment of adult patients with newly diagnosed ... chronic phase1. These new data, from the first ...
Cached Biology Technology:YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6
(Date:10/25/2014)... 2014 This report covers the specifics of ... in heavy pursuit of research due to its versatility ... to other RNA components. miRNA,s non-coding nature and ability ... for use as a biomarker for a variety of ... diagnostics for the advancement in therapeutic development. Furthermore there ...
(Date:10/25/2014)... , Oct. 23, 2014 Research ... "Biometrics Market in Europe 2014-2018" report to their ... helps to assess individuals on the basis of their ... identification of both physiological traits such as fingerprints, face ... and behavioral traits such as keystroke patterns and speech ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3
... fossil discovered in Tunisia represents the oldest known ancestor of ... mammals. The find is described in research published January 16 ... Julien Benoit and colleagues from the University of Science and ... cow ancestors have been found in Jamaica, but the Tunisian ...
... are facing a troubling consequence of their own success. They ... life expectancy. However, those same drugs will eventually cause the ... current treatments. With a new $3.4 million grant from ... leading a team of researchers who want to stay a ...
... launch pad or even in orbit. They start years before ... to expand our view and understanding of the planet. NASA ... for the Aerosol-Cloud-Ecosystem (ACE) mission, a satellite that "will dramatically ... clouds and aerosols," said ACE science lead David Starr of ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3PODEX experiment to reshape future of atmospheric science 2PODEX experiment to reshape future of atmospheric science 3PODEX experiment to reshape future of atmospheric science 4PODEX experiment to reshape future of atmospheric science 5
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
... The Cell Lab Quantas unique combination ... unsurpassed population resolution capabilities and accurate ... multiple excitation wavelengths, including UV, allowing ... of multi-color applications typically only achievable ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: